Physician profile
William Saway
NPI 1780675652
$4,954.13
in general payments reported to CMS, 2019-2025
36 companies · $717 in 2025
The $717 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $935 · 2020: $246 · 2021: $263 · 2022: $13.28 · 2023: $2,680 · 2024: $100 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,427 · Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,427.29 |
| Food and Beverage | $1,069.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Midmark Corporation | $2,602.17 | 2023 | |
| Lilly USA, LLC | $403.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $341.02 | 2019-2025 | Airsupra, Xigduo, Breztri |
| Pfizer INC. | $261.66 | 2019-2025 | |
| Novo Nordisk INC | $210.90 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $183.99 | 2019-2025 | Evenity |
| Janssen Pharmaceuticals, INC | $137.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $100.01 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.65 | 2019-2025 | Jardiance |
| Sanofi Pasteur INC. | $79.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $78.72 | 2019-2025 | Shingrix, Arexvy |
| Radius Health, INC. | $51.91 | 2019-2025 | |
| Kyowa Kirin, INC. | $43.36 | 2021 | |
| Horizon Therapeutics Plc | $36.16 | 2019 | |
| Exact Sciences Corporation | $34.41 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $31.54 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $30.12 | 2021 | |
| Abbott Laboratories | $29.78 | 2019-2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $23.77 | 2025 | Aptima |
| Flowonix Medical Incorporated | $23.76 | 2019 | |
| Philips North America LLC | $22.73 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bayer Healthcare Pharmaceuticals INC. | $19.96 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.06 | 2025 | Gvoke Hypopen |
| Medtronic, INC. | $18.40 | 2023 | Closurefast |
| Optinose US, INC. | $17.92 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.94 | 2025 | Lifevest |
| Daiichi Sankyo INC. | $14.91 | 2020 | |
| Dexcom, INC. | $14.85 | 2019 | |
| Tactile Systems Technology INC | $12.50 | 2019 | |
| Medtronic USA, INC. | $11.43 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Saway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.